NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of elotuzumab for previously treated multiple myeloma. If, after doing this, organisations still wish to consider elotuzumab for previously treated multiple myeloma, they should follow the advice on rational local decision-making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.

NICE will review the position at any point if the company indicates that it wishes to make a full submission.

ISBN: 978-1-4731-2420-2

  • National Institute for Health and Care Excellence (NICE)